

Refer a patient, and we'll keep you **in the loop** through their care.

Lumin Health provides FDA-approved Spravato® (esketamine) and intramuscular ketamine therapy at five locations in Massachusetts and Maryland. Here is who to refer, how to do it, and when you'll hear from us.

Who may benefit most from ketamine or esketamine

Your stuck patients

Failed 2+ antidepressants

Why: Bypasses traditional monoamine pathways.

Your critical patients

Acute suicidal ideation

Why: Can bring relief in hours to days, not weeks.

Your numb patients

Deep anhedonia

Why: Re-engages the brain's reward system.

Your rigid patients

Cognitive rigidity or OCD traits

Why: May increase neuroplasticity and quiet the default mode network.

WHAT HAPPENS AFTER YOU REFER

YOUR PATIENT



Referral



Consultation



Treatment



Transition

WHAT YOU HEAR FROM US



Confirmation

We confirm we received your referral and reach out to your patient.



Fit and next steps

We tell you what we found and what comes next, whether or not your patient starts treatment.



Progress reports

You get regular updates while your patient is in active care.



Coordinated handoff

We coordinate the transition back to your care when treatment ends.

INCLUSION CRITERIA

- Adults (18+) with MDD, PTSD, or OCD
- Inadequate response to 2+ antidepressant trials (exact requirements vary by insurer)
- Stable enough for outpatient specialty care
- Has a ride home after the 2-hour monitoring period

EXCLUSION CRITERIA

- Active psychosis or untreated mania
- Current pregnancy or lactation
- Recent stroke or vascular instability (certain aneurysms, AVMs, etc.)
- Acute substance intoxication



How to refer

lumin.health/refer-a-patient

Our secure, HIPAA-compliant form. Or call us directly:

617-863-8810

Sherri Crowley, LICSW

Director of Clinical Outreach and Provider Concierge
sherri.crowley@lumin.health

Ben Yudkoff, MD

Chief Medical Officer
ben@lumin.health

Locations: Brookline, Cambridge, Newton, and Woburn, MA • Bethesda, MD

Spravato® is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation. IM ketamine is used off-label.